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ABSTRACT
Replication of human immunodeficiency virus type 1 (HIV-1) is controlled by a variety of viral and
host proteins. The viral protein Tat acts in concert with host cellular factors to stimulate transcrip-
tional elongation from the viral long terminal repeat (LTR) through a specific interaction with a 59-
residue stem–loop RNA known as the trans-activation responsive element (TAR). Inhibitors of Tat-
TAR recognition are expected to block transcription and suppress HIV-1 replication. In previous
studies, we showed that 2-O-methyl (OMe) oligonucleotide mixmers containing locked nucleic acid
(LNA) residues are powerful steric block inhibitors of Tat-dependent trans-activation in a HeLa cell
reporter system. Here we compare OMe/LNA mixmer oligonucleotides with oligonucleotides con-
taining tricyclo-DNAs and their mixmers with OMe residues in four different assays: (1) binding to
the target TAR RNA, (2) Tat-dependent in vitro transcription from an HIV-1 DNA template directed
by HeLa cell nuclear extract, (3) trans-activation inhibition in HeLa cells containing a stably inte-
grated firefly luciferase reporter gene under HIV-1 LTR control, and (4) an anti-HIV -galactosi-
dase reporter assay of viral infection. Although tricyclo-DNA oligonucleotides bound TAR RNA
more weakly, they were as good as OMe/LNA oligonucleotides in suppressing in vitro transcription
and trans-activation in HeLa cells when delivered by cationic lipid. No inhibition of in vitro tran-
scription and trans-activation in HeLa cells was observed for tricyclo-DNA/OMe mixmers, even
though their affinities to TAR RNA were strong and their cell distributions did not differ from
oligonucleotides containing all or predominantly tricyclo-DNA residues. Tricyclo-DNA 16-mer
showed sequence-specific inhibition of -galactosidase expression in an anti-HIV HeLa cell reporter
assay.
INTRODUCTION
TRANSCRIPTION of the human immunodeficiency virustype 1 (HIV-1) genome is activated by a mechanism
that involves the interaction of the viral protein Tat with
the trans-activation responsive element (TAR) RNA,
which is found at the 5-leader sequence of the HIV-1
mRNA (for a recent review, see Brady and Kashanchi,
2005). Tat promotes the binding of the positive transcrip-
tional elongation factor P-TEFb, which is composed of
two proteins, cyclin T1 and the kinase cdk9. The forma-
tion of a quaternary complex between Tat, P-TEFb and
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TAR leads to an increase in the stability and processivity
of RNA Pol II and thus enhances substantially transcrip-
tional elongation from the HIV-1 long terminal repeat
(LTR) promoter. The high degree of conservation of the
RNA sequence of the apical region of TAR makes this a
promising target for anti-HIV drug development. Over
the last several years, a number of peptides, pep-
tidomimetics, aminoglycoside antibiotics, and nonpep-
tidic small molecules of different types have been sug-
gested as Tat-competitive binders to TAR RNA (for
recent reviews, see Krebs et al., 2003; Richter and Palu,
2006). However, none of these compounds has proved
suitable for clinical development.
Synthetic oligonucleotides and their analogs that are
complementary to the apical region of TAR RNA are ob-
vious alternative inhibitors of Tat-mediated trans-activa-
tion (for review, see Fabani et al., 2006; Richter and Palu,
2006; Turner et al., 2006). Since the potential of
oligodeoxynucleotides to inhibit viral replication in cell
culture was discovered (Zamecnik and Stephenson,
1978), numerous approaches for targeting of HIV-1 TAR
RNA have emerged following distinct mechanistic path-
ways. Thus, anti-TAR antisense oligodeoxynucleotides
with diester or phosphorothioate linkages were designed
to activate RNase H and cleave the RNA moiety of a
DNARNA heteroduplex (Vickers et al., 1991; Boulmé
et al., 1997). Other strategies involving cleavage of RNA
use oligonucleotide modifications that either form small
ribozymes when bound to the target (Bramlage et al.,
1998), or are linked to a ribozyme domain (Puerta-Fer-
nández et al., 2003). Furthermore, the discovery of the
phenomenon of RNA interference (RNAi) increased the
impact of the oligonucleotide field in antiviral therapy
(for a recent review, see Morris and Rossi, 2006). Small
interfering (si) RNA targeted against TAR RNA has been
shown to successfully suppress HIV-1 replication
(Jacque et al., 2002), but more recently TAR was found
to be a relatively unfavorable target for siRNA (Yoshi-
nari et al., 2004). Recently, nuclease-resistant modified
oligonucleotide aptamers have been selected in vitro to
bind tightly to the TAR RNA and form a loop–loop kiss-
ing complex and block Tat binding and transcriptional
elongation (Darfeuille et al., 2002a,b; Kolb et al., 2005).
Steric block oligonucleotides that are unable to induce
RNase H cleavage have been used to inhibit viral replica-
tion (recently reviewed in Ivanova et al., 2006). We
showed previously that 12-mer oligonucleotides contain-
ing all 2-O-methyl (OMe) nucleotides, or a mixture of
OMe and locked nucleic acid (LNA) monomers
(Koshkin et al., 1998; Wahlestedt et al., 2000), or 12-mer
peptide nucleic acid (PNA) prevented HIV-1 Tat binding
to TAR RNA and inhibited Tat-dependent in vitro tran-
scription (Arzumanov and Gait, 1999; Arzumanov et al.,
2001a). Furthermore, we found that 12-mer or 16-mer
steric-block OMe/LNA mixmer oligonucleotides com-
plementary to TAR effectively inhibited Tat-dependent
trans-activation when delivered by cationic lipids in a
HeLa cell reporter assay (Arzumanov et al., 2001b,
2003). The 16-mer OMe/LNA mixmer targeted to TAR
was found to inhibit dose-dependently and sequence-
specifically syncitia formation induced by HIV-1 infec-
tion when delivered by cationic lipids into HeLa T4 LTR
cells (Brown et al., 2006). PNA complementary to TAR
and their peptide conjugates are also promising analogs
that are capable of blocking reverse transcription and
Tat-dependent trans-activation in reporter assays and
also have shown anti-HIV activity (Kaushik et al.,
2002a,b; Tripathi et al., 2005; Turner et al., 2005b).
By use of fluorescently labeled OMe/LNA oligonu-
cleotides, we concluded that about 50% LNA units was
needed to obtain both good cellular and nuclear uptake
when packaged by cationic lipids (Arzumanov et al.,
2003). Because the replacement of LNA units by iso-
meric -LNA, which has completely different stereo-
chemistry, did not reduce the trans-activation inhibitory
activity, it seemed that the hydrophobicity of LNA
monomers may help in cationic lipid packaging as well
as directing the oligonucleotide to the nucleus. Recently,
we showed that oligonucleotide analogs containing cer-
tain amino modifications: N3-P5-phosphoamidates,
N3-P5-phosphothioamidates, OMe/2-amino-LNA or
OMe/2-amino-LNA/2-glycylamino-LNA mixmers tar-
geted to HIV-1 TAR region could also inhibit trans-acti-
vation in our cell reporter system (Ivanova et al., 2005).
Another type of conformationally restricted oligonu-
cleotide analog, tricyclo-DNA, has a rather hydrophobic
sugar unit, elicits strong RNA-binding ability, and has
good biostability (Steffens et al., 1999; Renneberg and
Leumann, 2002). Lipofectamine-mediated delivery into
HeLa cells of nanomolar concentrations of a 17-mer tri-
cyclo-DNA complementary to the 3-cryptic splice site
of -globin mRNA was shown to result in correction of
aberrant splicing with up to 100-fold enhanced efficiency
relative to the corresponding OMe-phosphorothioate
RNA (Renneberg et al., 2002). Furthermore, in analysis
by fluorescence microscopy, a stronger nuclear localiza-
tion of 15-mer tricyclo-DNA compared with the corre-
sponding all LNA oligonucleotide was seen following
Lipofectamine-mediated transfection, which was sug-
gested as a possible reason for the four to five times
higher observed antisense efficacy of tricyclo-DNA (Ittig
et al., 2004). However, mixmers of OMe/LNA were not
studied in these assays, nor were mixmers of tricyclo-
DNA with OMe units. 
Here we show that 16-mer tricyclo-DNA oligonu-
cleotides are able to inhibit Tat-dependent trans-activa-
tion in HeLa cells as effectively as OMe/LNA mixmers
when delivered by Lipofectamine 2000, but tricyclo-
DNA mixmers with OMe are ineffective. Neither TAR
RNA-binding ability nor nuclear delivery ability, as
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judged by confocal microscopy, was correlated with ef-
fectiveness at Tat-dependent trans-activation inhibition
in HeLa cells. However there was good correlation with
their ability to inhibit Tat-dependent transcription in
vitro. A 16-mer tricyclo-DNA oligonucleotide showed
sequence-specific inhibition of -galactosidase expres-
sion in an anti-HIV reporter assay, and only a little less
effectively than a 16-mer OMe/LNA mixmer.
MATERIALS AND METHODS
RNA, tricyclo-DNA, OMe/tricyclo-DNA, and 
OMe/LNA oligonucleotides
39-mer model TAR RNA (see Fig. 1A, below) and
OMe/LNA mixmers containing a 3-FAM label (Ic, IIc, see
Table 1) were chemically synthesized as described previ-
ously (Mestre et al., 1999; Arzumanov et al., 2001a,b). The
3-label was 3-(6-fluorescein) CPG (Glen Research).
Tricyclo-DNA and OMe/tricyclo-DNA oligonucleotides
(Ia, Ib, IIa, IIm, and IIb) were prepared on a 1.3 mol scale
on a Pharmacia Gene Assembler Special™ or a PerSeptive
Biosystems Expedite DNA Synthesizer using the modified
phosphoramidite chemistry procedure as reported previ-
ously (Renneberg and Leumann, 2002; Renneberg et al.,
2002; Ittig et al., 2004). OMe phosphoramidites were ob-
tained from Glen Research and LNA phosphoramidites
were from Exiqon. All oligomers were synthesized with a
3-fluorescein label using LC fluorescein CPG (Roche Di-
agnostics). Deprotection and cleavage from the solid sup-
port were carried out under standard conditions (conc. NH3,
16 hours, 55°C). Crude oligonucleotides were purified by
reversed phase high-performance liquid chromatography
(HPLC). The molecular masses of all oligonucleotides
were confirmed by ESI mass spectrometry.
Oligonucleotide-TAR RNA-binding assay
The binding affinities of the oligonucleotides to 32P-la-
beled 39-mer TAR RNA in two different buffers were eval-
uated by a polyacrylamide gel mobility-shift assay as de-
scribed previously (Arzumanov et al., 2001a,b). Apparent
dissociation constants (KD) shown (Table 2) are calculated
as the average value from a minimum of three experiments.
Tat-dependent in vitro transcription
Tat-dependent in vitro transcription was carried out in
the presence of oligonucleotide inhibitors using a DNA
template, which is a fragment (346 to 524) of plas-
mid p10SLT and carries the wild-type HIV-1 LTR (strain
NL4-3) as described previously (Arzumanov et al.,
2001b). The oligonucleotides were incubated with 10 nM
of the template at 30°C for 20 minutes in a 40-L reac-
tion mixture containing 15 L HeLa cell nuclear extract,
80 mM KCl, 2 mM MgCl2, 20 mM HEPES pH 7.9, 2
mM DTT, 10 M ZnSO4, 10 mM creatine phosphate,
100 g  ml1 creatine kinase, 1 g poly[d(I-C)] (Roche,
Nutley, NJ), 50 M ATP, GTP, and CTP, 5 M UTP (in-
cluding [-32P]UTP, 10 Ci), 1 U  l1 RNasin
(Promega, Madison, WI), and 200 ng recombinant Tat
protein. The reaction products were resolved by 6% poly-
acrylamide gel electrophoresis (PAGE) with 7 M urea
and detected by phosphoimaging.
Tet-off/Tat/luc-f/luc-R HeLa cell line
HeLa cells containing the stably integrated HIV-1 Tat
gene under Tet-off promoter, firefly luciferase gene un-
der the HIV-1 LTR, and the Renilla luciferase gene under
cytomegalovirus (CMV) promoter, described previously
(Arzumanov et al., 2001b), were grown in Dulbecco’s-
modified Eagle medium (DMEM) medium supple-
mented with 10% Tet System Approved fetal bovine
serum (FBS) (Clontech, Palo Alto, CA), penicillin, and
streptomycin at 37°C under 5% CO2/95% air.
Tat-dependent trans-activation in HeLa cells
Tat-dependent trans-activation experiments in the
presence of oligonucleotide inhibitors were carried out as
TABLE 1. OLIGONUCLEOTIDES USED IN THIS STUDYa
No. Oligonucleotide analog Sequence 5–3
Ia 12 TAR 1xOMe/11xTricyclo-DNA FAM ctc cca ggc tcA-FAM
Ib 12 TAR 7xOMe/5xTricyclo-DNA FAM cUc CcA GGc UcA-FAM
Ic 12 TAR 7xOMe/5xLNA FAM CUC CCA GGC UCA-FAM
IIa 16 TAR Tricyclo-DNA FAM ctc cca ggc tca gat c-FAM
IIm 16 TAR Tricyclo-DNA-mism FAM ctc cca ccc tca cat c-FAM
IIb 16 TAR 10xOMe/6xTricyclo-DNA FAM cUc CcA GGc UcA GAt C-FAM
IIc 16 TAR 10xOMe/6xLNA FAM CUC CCA GGC UCA GATC-FAM
aTricyclo-DNA residues are shown in lower case. Capitals show 2-O-Me nucleotides. Underlined monomers are
LNA nucleotides (5-methyl C or T).
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described previously (Arzumanov et al., 2003). Cells
were aliquoted in two identical 96-well plates at concen-
tration of 104 cells per well and incubated at 37°C for 18
hours. One of the plates was used in the luciferase assay
and the other in the cytotoxicity assay. Oligonucleotides
were prepared at a concentration of 1 M in serum-free
Opti-MEM (Invitrogen, San Diego, CA). To each solu-
tion was added an equal volume of cationic lipid Lipofec-
tamine 2000 in Opti-MEM (10 l lipid per 1 mL
medium). Complexes were formed at room temperature
for 20 minutes. Subsequent dilutions were made from
this oligonucleotide/lipid mixture and added to HeLa
cells (100 L of oligonucleotide/lipid dilution per well),
which had been briefly washed previously with phos-
phate-buffered saline solution (PBS). After 3 hours of
transfection, the medium was replaced with 100 L of
DMEM/10% fetal bovine serum (FBS) and cells were in-
cubated for 18 hours at 37°C, after which the luciferase
and cell toxicity levels were measured.
Luciferase assay
Cells were lysed and the lysates were analyzed using a
Dual Luciferase Reporter Assay System (Promega). The
relative light units for both firefly and Renilla luciferase
were read on a Berthold Detection Systems Orion Mi-
croplate luminometer. Each data point was averaged over
two replicates of at least three experiments.
Toxicity assay
The proportion of live cells was determined by ab-
sorbance measurement at 490 nm using a Molecular De-
vices Emax microplate Reader (Menlo Park, CA) after
treatment with Cell Titer 96 AQueous One Solution As-
say (Promega). Each data point was averaged over two
replicates of at least three experiments.
Confocal microscopy
Oligonucleotide cell distribution was detected using
confocal microscopy, as described previously (Arzu-
manov et al., 2003). Hela cells were plated on eight-well
Lab-Tek chambered coverglasses (Fisher Scientific,
Pittsburgh, PA) in DMEM/10% FBS at 2  104 cells per
well and incubated at 37°C overnight. After washing
with PBS, cells were incubated with 200 L of oligonu-
cleotide/Lipofectamine 2000 complex in Opti-MEM for
3 hours and with 50 L of 20 g mL1 hydroethidine in
Opti-MEM for 30 minutes. The cell images were taken in
Opti-MEM (without Phenol Red) medium with a Radi-
ance 2100 confocal system using a Nikon Eclipse TE300
inverted microscope, a 40 Planapo objective, NA 1.3.A
60 Planapo, NA 1.4.A, and a 488-nm argon laserline to
excite the fluorescein (FAM) label. An HQ 515/30 emis-
sion filter was used for observation of the green emis-
sion. Hydroethidine was excited with a 543-nm (green)
HeNe laser and detected using a HQ 570LP (orange)
emission filter. A dual fluorescence method was used
with a differential interference contrast (DIC) transmis-
sion channel. The images in the three channels were
viewed sequentially at approximately one frame per sec-
ond with a scanning resolution of 512  512 pixels, and
a Kalman average of 10 frames.
Inhibition of HIV infectivity in HeLa P4 cells
Infectivity was assayed on HeLa P4 cells expressing
receptors CD4 and CXCR4 and carrying the stably inte-
grated lacZ gene under the control of the HIV-1 LTR




No. Oligonucleotide analog TK-80a bufferb
Ia 12 TAR 1xOMe/11xTricyclo-DNA FAM 131.7  15.5 9.9  3.5
Ib 12 TAR 7xOMe/5xTricyclo-DNA FAM 176.2  33.9 23.2  5.1
IIa 16 TAR Tricyclo-DNA FAM 65.8  7.5 5.5  0.6
IIm 16 TAR Tricyclo-DNA-mism FAM n.b.c n.b.c
IIb 16 TAR 10xOMe/6xTricyclo-DNA FAM 98.1  4.9 4.5  0.1
Ic 12 TAR 7xOMe/5xLNA FAM 5.7  0.7d 1.1  0.3d
IIc 16 TAR 10xOMe/6xLNA FAM 9.3  0.4d 3.3  0.8d
aTK-80: 50 mM Tris.HCl pH 7.4; 80 mM KCl.
bTranscription buffer: 20 mM HEPES, pH 7.9; 10 M ZnSO4; 2 mM DTT; 80 mM KCl; 3 mM MgCl2; 10 mM 
creatine phosphate.
cNo binding up to 10 M concentration.
dData published before (Arzumanov et al., 2003) and shown here for comparison.
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(gift of J.L. Darlix, INSERM U412 ENS, Lyon) by a
modification of a previously published method (Ventura
et al., 1999). P4 cells were plated using 100 L of
DMEM plus 10% (vol/vol) FBS, 2 mM glutamine, 500
g ml1 of antibiotic G418 (Gibco-BRL) in two identical
96-well plates at 10,000 cells per well. One of the plates
was used for the -galactosidase activity and the other
for the cytotoxicity assay. After incubation overnight at
37°C under 5% CO2, the supernatant was discarded and
the cells were washed with PBS.
For delivery by cationic lipid mixture, 1 M oligonu-
cleotide and 10 g mL1 Lipofectamine 2000 in DMEM
medium was prepared according to the manufacturer’s
manual (Invitrogen). After 20 minutes at room tempera-
ture, subsequent dilutions were prepared from the oligo-
nucleotide/Lipofectamine complex. HeLa P4 cells were
incubated with this complex for 3 hours, washed with
PBS, and incubated in DMEM/10% FBS. After incuba-
tion for 18 hours at 37°C under 5% CO2, the supernatant
was discarded and 200 L of fresh medium containing
HIV-1LAI was added. Then 24 hours later, the supernatant
was discarded and the wells were washed three times
with 200 L of 9% NaCl solution. Each well was refilled
with 200 L of a reaction buffer containing 50 mM Tris-
HCl pH 8.0, 100 mM -mercaptoethanol, 0.05%
(vol/vol) Triton X-100, and 5 mM 4-methylumbelliferyl-
-D-galactosidase (4-MUG). After 3 hours at 37°C, the
reaction products were measured in a fluorescence mi-
croplate reader (Cytofluor II) at 405 nm.
For the toxicity assay, CellTiter 96 AQueous One Solu-
tion Assay (Promega) was used. The absorbance at 490
nm was read using a Dynex MRX model 96 Well Mi-
croplate Reader (Dynex Technologies). Each data point
was averaged over two replicates of three separate exper-
iments. The -galactosidase activities results were nor-
malized to the absorbance data from the toxicity assay,
which reflects the amount of live cells.
RESULTS
Binding of Tricyclo-DNA containing oligonucleotides to
39-mer TAR RNA
To prevent the Tat-TAR interaction and have the po-
tential for trans-activation inhibition, steric block
oligonucleotides containing nucleotide analogues (Fig.
1B–D) must be able to bind specifically and strongly to
the target TAR RNA. We chemically synthesized a 12-
mer containing 11 tricyclo-DNA units and a single OMe
at the 3-end (Ia, Table 1) and a 16-mer with all tricyclo-
DNA units (IIa), as well as a 12-mer mixmer with 7
OMe and 5 tricyclo-DNA units (Ib) and a 16-mer with
6 tricyclo-DNA units and 10 OMe units (IIb), com-
plementary to the apical region of a 39-mer model TAR
RNA (Fig. 1A; Mestre et al., 1999). All oligonucleotides
contained a 3-FAM label for cell uptake studies. We
measured the ability of these oligonucleotides to bind in
vitro to a 39-mer model TAR RNA at 37°C in either of
two buffers, one with a moderate salt concentration and
the second with much higher salt concentration and other
additives used in vitro transcription assays.
The results (Table 2) show that the apparent dissociation
constants of oligonucleotides containing tricyclo-DNA are
higher than for the corresponding 12-mer-FAM and 16-
FIG. 1. (A) HIV-1 39-mer model TAR RNA stem–loop structure and the binding sites for steric block oligonucleotides with dif-
ferent length containing nucleosides of three types: tricyclo-DNA (B), 2-O-Me (C), and LNA (D).
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mer OMe/LNA mixmers from our previous work (Arzu-
manov et al., 2003). 16-mer tricyclo-DNA containing
oligomers had stronger binding affinity to the target than
similar 12-mers in both buffers, whereas with OMe/LNA
mixmers this is reversed (Table 2 and Arzumanov et al.,
2003). The binding is sequence-specific, since mis-
matched tricyclo-DNA 16-mer IIm did not bind to the
TAR RNA in concentrations up to 10 M. A scrambled
tricyclo-DNA 16-mer (ATCGCTCGCACCATGC-FAM)
also failed to bind TAR RNA (data not shown). 
The 12-mer mixmer Ib showed generally weaker bind-
ing than corresponding oligonucleotide containing
mostly tricyclo-DNA residues Ia, but the 16-mer mixmer
IIb in transcription buffer had similar KD value to the all
tricyclo-DNA 16-mer IIa. The binding to TAR RNA is
stronger for all oligonucleotides tested in transcription
buffer than for TK buffer, as was observed previously for
OMe/LNA mixmers (Arzumanov et al., 2001b, 2003).
Under these conditions, all of the exactly matched tricy-
clo-DNA containing oligonucleotides have sufficiently
strong binding (KD 4.5 to 23.2 nM) for them to be suit-
able for consideration as steric block agents.
Tat-dependent in vitro transcription
A good steric block oligonucleotide inhibitor must be
able to compete effectively for the target TAR RNA dur-
ing active transcription. This is a more rigorous dynamic
test than equilibrium binding to TAR. Thus, we tested the
ability of tricyclo-DNA containing oligonucleotides to
inhibit Tat-dependent transcription in vitro from a HIV-1
DNA template containing the TAR sequence as directed
by HeLa cell nuclear extract (Fig. 2). A representative
PAGE analysis (Fig. 2A) shows the levels of 32P-labeled
transcription run-off products. In the control lanes 1 and
2, the Tat plus and Tat minus band intensities are seen,
and this shows the transcription enhancement due to the
presence of Tat. When 16 TAR tricyclo-DNA IIa was
added in the presence of Tat, a transcription reduction
was seen as the oligonucleotide concentration was in-
creased (Fig. 2A, lanes 3–7). Furthermore, the inhibition
is sequence specific, since the mismatched 16 TAR tricy-
clo-DNA IIm showed no inhibitory activity (Fig. 2A,
lanes 8–12). Surprisingly, among the rest of oligonu-
cleotides tested (Table 1), only 12 TAR tricyclo-DNA Ia
showed inhibitory activity (Fig. 2B), and there was no ef-
fect of either of the OMe mixmers containing tricyclo-
DNA (Ib or IIb). The inhibition levels observed for both
active sequences Ia and IIa are quite similar. They are
slightly higher than those we obtained and previously
published for 16-mer OMe/LNA IIc and slightly lower
than those for 12-mer OMe/LNA Ic (Arzumanov et al.,
2003).
Tat-dependent trans-activation in HeLa cells
Because HIV-1 Tat-dependent trans-activation occurs
in the cell nucleus, the steric block oligonucleotide must
FIG. 2. Inhibition of in vitro transcription from an HIV-1 DNA template, which contains the TAR sequence, by steric block
oligonucleotides. (A) A typical autoradiograph showing the transcription run-off product in the presence (lane 1) or absence (lane
2) of HIV-1 Tat protein, and the effect of increasing concentration (0.125, 0.25, 0.5, 1, and 2 M) of oligonucleotides in the pres-
ence of Tat (IIa, lanes 3–7 or IIm, lanes 8–12). (B). The amount of transcript product is shown as a plot of the intensity of the cor-
responding band in the autoradiograph (A) against oligonucleotide concentration. Data presented were averaged over at least three
experiments, but error bars are not shown for clarity. The standard deviation for each data point was less than 30% of the averaged
value.
be able to enter the nucleus and bind to the TAR RNA to
prevent docking of Tat and host cellular factors that trig-
ger transcriptional elongation. The nuclear inhibition ac-
tivity of the oligonucleotides was tested in a double-lu-
ciferase HeLa cell reporter system (Arzumanov et al.,
2001b, 2003). The HeLa cells contain three stably inte-
grated plasmids, one expressing the HIV-1 Tat under
Tet-off promoter control, the second expressing firefly
luciferase under HIV-1 LTR control, and the third ex-
pressing Renilla luciferase under CMV promoter control.
Specific knockdown of firefly luciferase expression is
obtained only if the oligonucleotide is taken up by a large
majority of cells and is able to inhibit the Tat-dependent
transcription from the HIV-1 LTR by steric blocking of
the TAR RNA target during the assay period. There
should be no effect on the Renilla luciferase expression,
which is a control for nonspecific inhibition of protein
synthesis.
We tested all oligonucleotides (Table 1) up to 500 nM
concentration in this cell assay with cationic lipid–medi-
ated delivery for 3 hours, followed by cell growth for 18
hours in the absence of oligonucleotide challenge. Two
alternative cationic lipids, Oligofectamine or Lipofecta-
mine 2000, were used. Under these conditions, all
oligonucleotides showed 80% cell viability. Dose-de-
pendent knockdown of firefly luciferase expression was
observed with both cationic lipids for the sequences con-
taining mostly tricyclo-DNA monomers Ia and IIa and
the levels of inhibition were similar to these for the
OMe/LNA controls with the same length Ic and IIc (Fig.
3A, Lipofectamine 2000 data shown). Activity levels
when oligonucleotides were delivered with Oligofecta-
mine were a little lower (data not shown). Neither of the
mixmers Ib or IIb was active with either of the cationic
lipids. The mismatched 16–mer IIm did not inhibit Tat-
dependent trans-activation.
The Renilla luciferase expression level was affected
only in the case of 12–mer Ia (Fig. 3B). However 16
TAR tricyclo-DNA IIa did not show any effect on the Re-
nilla luciferase levels, which confirms the sequence-spe-
cific cellular activity. Both 12–mer Ia and 16–mer IIa
were tested in the cell assay with unassisted delivery for
24 hours, but neither showed any firefly luciferase in-
hibitory activity up to 10 M concentration (data not
shown), which is consistent with previous observations
in other assay systems (Ittig et al., 2004).
Note that some increases in luciferase fluorescence for
particular constructs are occasionally observed as con-
centration of oligonucleotide/cationic lipid is increased
(Fig. 3), reflecting the sensitivity of the assay to additives
in cell growth conditions, as previously observed (Arzu-
manov et al., 2001b, 2003; Turner et al., 2005a,b). A sig-
nificant reduction in Renilla luciferase expression is ex-
pected if there is any nonspecific transcription/translation
suppressive effect, which is only seen in the case of oli-
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gonucleotide Ia. Thus, in the case of Ia, the firefly lucif-
erase reduction level may be partly due to a nonspecific
effect. We do not have an explanation for the nonspecific
effect seen here, which in our experience is rare in this
assay for oligonucleotides not containing phosphorothio-
ate linkages (Arzumanov et al., 2001b, 2003).
Oligonucleotide uptake into HeLa cells
Because the steric block oligonucleotides were 3-fluo-
rescein-labeled, we were able to observe their cell uptake
FIG. 3. Inhibitory effect of steric block oligonucleotides de-
livered by cationic lipid Lipofectamine 2000 in the HeLa re-
porter assay. (A) Luminescence levels measured due to firefly
luciferase activity (normalized to cell viability count) after cell
incubation with oligonucleotides Ia, Ib, Ic, IIa, IIm, IIb, or IIc,
shown as percentage of firefly luciferase luminescence of un-
treated cells (the last bar in each series). Left to right: oligonu-
cleotide concentrations 500, 250, 125, 62.5, and 0 nM, respec-
tively. (B) Luminescence levels measured due to Renilla
luciferase activity. Note that in this assay the batch of control
oligonucleotide IIc did not contain a 3-fluorescein label, but
this has already been shown to make no difference to the cellu-
lar activity of such oligonucleotides (Arzumanov et al., 2003).
A
B
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by confocal microscopy. All newly synthesized oligonu-
cleotides Ia–IIb (Table 1) were taken up well by most of
the HeLa cells treated when delivered with Lipofecta-
mine 2000 for 3 hours (Fig. 4), but none of them was
taken into the cells when incubated in the absence of
cationic lipids, even after 24 hours (data not shown). The
confocal microscopy images of the cells transfected with
16-mers tricyclo-DNA IIa, OMe/tricyclo-DNA mixmer
IIb, and OMe/LNA mixmer IIc in the presence of
cationic lipid are shown in Fig. 4. Both tricyclo-DNA
containing oligonucleotides IIa and IIb (Fig. 4A,B)
showed strong nuclear uptake with some remaining fluo-
rescence in cytosolic compartments, even though the
mixmer IIb did not have any inhibitory activity in the
HeLa cell reporter system (Fig. 3). This shows that the
inactivity of mixmer IIb is not due to poor nuclear pene-
tration.
Although previous studies showed a stronger nuclear
uptake for 15–mer all-tricyclo-DNA compared with a
15–mer all LNA oligonucleotide (Ittig et al., 2004), no
significant difference in distribution within the cells was
found for the tricyclo-DNA containing oligonucleotide
IIa and tricyclo-DNA/OMe mixmer IIb compared to the
OMe/LNA mixmer IIc (Fig. 4C). These results show that
both tricyclo-DNA and LNA units are capable of direct-
ing excellent cell uptake and nuclear entry in the pres-
ence of cationic lipids. Note that we have previously
shown that a FAM-labeled all OMe 16-mer oligonucleo-
tide was poorly taken up by HeLa cells under similar
conditions and failed to show inhibition of Tat-dependent
trans-activation (Arzumanov et al., 2003).
Inhibition of HIV infectivity in HeLa P4 cells
The most promising steric block oligonucleotide can-
didate 16 TAR tricyclo-DNA IIa and the corresponding
OMe/LNA mixmer IIc were tested for inhibition of HIV-
1 infectivity in a HeLa P4 cell line expressing receptors
CD4 and CXCR4 and carrying the stably integrated lacZ
gene under the control of the HIV-1 LTR (Ventura et al.,
1999; Brown et al., 2006). The transfections were carried
out with Lipofectamine 2000 assistance for 3 hours. At
18 hours later HIV-1LAI was added and the cells were in-
cubated for a further 24 hours. Dose-dependent knock-
down of HIV-1-induced -galactosidase expression was
observed for 16–mer tricyclo-DNA IIa (Fig. 5) for con-
centrations up to 1 M (25% inhibition), whereas no
HIV-1 inhibitory activity was seen for the mismatched
control IIm. A little higher inhibitory activity was mea-
sured for 16–mer OMe/LNA mixmer IIc (40% at 1 M),
FIG. 4. Live HeLa cell uptake of 16 TAR tricyclo-DNA FAM IIa (A), 16 TAR 10xOMe/6xTricyclo-DNA FAM IIb (B), and 16
TAR 10xOMe/6xLNA FAM IIc (C) when delivered by Lipofectamine 2000. The cell nucleus is stained red (hydroethidine; see
Materials and Methods). Top panels: The FAM-labeled oligonucleotides show a green fluorescence, seen here as white patches.
Bottom panels: Differential interference contrast (DIC) transmission channel showing cell outlines.
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which is very similar to that obtained in an analogous
anti-HIV-1 syncitia reduction assay for the same oligo-
nucleotide from another recent study (Brown et al.,
2006). No inhibitory effect was seen for a scrambled 16-
mer OMe/LNA oligonucleotide (AUCGCUCGCAC-
CATGC, LNA underlined, data not shown). These re-
sults show that tricyclo-DNA oligonucleotides can
exhibit sequence-dependent antiviral activity in a similar
way to OMe/LNA mixmers.
DISCUSSION
Prerequisites for therapeutic applications of antisense
oligonucleotides are high binding affinity to the RNA
target and good resistance to degradation by cellular nu-
cleases. Several analog types fulfil these criteria. Espe-
cially attractive are analogs where the sugar moiety is
conformationally restricted, such that preorganization of
the structure of the oligonucleotide single strand entropi-
cally favors high stability upon duplex formation.
Among the best such analogs are LNA (Koshkin et al.,
1998), hexitol nucleic acids (HNA) (Van Aerschot et al.,
1995), cyclohexene nucleic acids (CeNA) (Wang et al.,
2000), bicyclo-DNA (Tarköy et al., 1994), and tricyclo-
DNA (Steffens and Leumann, 1999). Tricyclo-DNA
showed a very high affinity for RNA and an increased
biostability compared with many other analog types. 
The only previous comparative study of tricyclo-DNA
was with all-LNA oligonucleotides (Ittig et al., 2004).
Although LNAs were superior in binding RNA, tricyclo-
DNA oligonucleotide 9-15 mers targeted against 3 and
5 splice sites of exon 4 of cyclophilin A pre-mRNA
showed at least four to five times stronger nuclear anti-
sense effects than corresponding all LNA oligonu-
cleotides upon Lipofectamine-mediated transfection into
HeLa cells. It was shown that tricyclo-DNA was more
strongly taken up into the cell nucleus, perhaps due to a
more hydrophobic backbone (Ittig et al., 2004). Previ-
ously, we reported that LNA mixmers with OMe
monomers are highly effective in inhibition of HIV-1
Tat-dependent trans-activation in a HeLa cell double-lu-
ciferase reporter assay with cationic lipid delivery (Arzu-
manov et al., 2001b, 2003) and may have advantages
over all-LNA oligonucleotides. Therefore, it was impor-
tant to compare tricyclo-DNA with OMe/LNA mixmers
and also to determine to what extent tricyclo-DNA could
be mixed with OMe residues to perhaps enhance activity
further.
Our results show that tricyclo-DNA 12-mer Ia with 11
tricyclo units and the all tricyclo-DNA16–mer IIa behave
very similarly to the corresponding OMe/LNA mixmers
Ic and IIc, respectively in: (1) ability to inhibit Tat-de-
pendent in vitro transcription (Fig. 2), (2) ability to in-
hibit Tat-dependent trans-activation and thus firefly lu-
ciferase gene expression in our HeLa cell reporter system
FIG. 5. Inhibition of HIV infectivity in HeLa P4 cells by 16 TAR tricyclo-DNA IIa, mismatched control IIm, and 16 TAR
OMe/LNA IIc (without 3-FAM) delivered with Lipofectamine 2000. Bars left to right represent -galactosidase activity levels,
normalized to cell viability, for oligonucleotide concentrations 1, 0.5, 0.25, and 0 M, respectively
with cationic lipid–mediated delivery (Fig. 3), and (3)
ability to enter the cell nucleus (Fig. 4). These similarities
occurred despite the fact that 12-mer tricyclo-DNA Ia
showed weaker binding affinity to TAR RNA compared
to 12-mer OMe/LNA oligomer Ic (Table 2), although the
difference in KD was less apparent for 16-mers IIa and IIc
in transcription buffer.
By contrast, tricyclo-DNA mixmers with OMe units Ib
and IIb had binding constants to TAR RNA in the same
range as tricyclo-DNAs Ia and IIa (Table 1) and were
taken into the cell nucleus (Fig. 4), but did not inhibit ei-
ther Tat-dependent in vitro transcription (Fig. 2) or Tat-
dependent trans-activation in the HeLa cell assay (Fig.
3). Thus, tricyclo-DNA mixmers with OMe must have
very different properties to OMe/LNA mixmers within
cells and are clearly unable to compete sufficiently for
the TAR target in the presence of the active Tat-depen-
dent transcription system, even though the equilibrium
RNA binding strengths would have appeared to be per-
fectly sufficient. We also found that a mixmer containing
tricyclo-DNA and LNA units was inactive in inhibition
of Tat-dependent in vitro transcription and in the HeLa
cell assay (data not shown). The results show that RNA
binding strength and the ability to enter the cell nucleus
when delivered by cationic lipid are not reliable enough
predictors alone of nuclear steric block activity. In the
case of the TAR target, the ability to inhibit Tat-depen-
dent in vitro transcription is an additional requirement
and a better predictor of cell activity.
For the Tat-TAR model, the ultimate goal is to select
candidate steric block oligonucleotide types as potential
antivirals. In this respect, the TAR 16-mer tricyclo-DNA
appeared a little less active than 16-mer OMe/LNA oli-
gonucleotide in the HeLa P4 cell -galactosidase HIV re-
porter assay when transfected with cationic lipid (Fig. 5).
The activity level of the 16-mer OMe/LNA oligonucleo-
tide was very similar to that obtained in a syncitia reduc-
tion assay previously reported with the same lipofection
agent (Brown et al., 2006). Recent studies of the anti-
HIV activity of PNA-peptides targeted to TAR (Tripathi
et al., 2005) suggest that inhibition of HIV infection may
reflect more the ability to block reverse transcription of
the HIV viral RNA at the TAR site within cytosolic com-
partments rather than inhibition of Tat-dependent gene
expression from an integrated HIV provirus within the
cell nucleus. The different levels of anti-HIV activity of
tricyclo-DNA and OMe/LNA 16-mers we observed is
consistent with this interpretation. We are currently ex-
tending our own studies of PNA–peptide conjugates tar-
geted to TAR (Turner et al., 2005b) to address these is-
sues and it will thus be of importance to compare
tricyclo-DNA, OMe/LNA, and PNA in their abilities to
block reverse transcription in vitro, in infected cells and
in HIV virions, as well as other parameters such as cell
delivery, to adequately assess their antiviral potential.
In summary, we have shown that a 16-mer all tricyclo-
DNA oligonucleotide targeted to HIV-1 TAR region acts
sequence specifically as an effective steric block inhibi-
tor of Tat-dependent trans-activation in vitro and in Hela
cells as well as of HIV infectivity when delivered with
cationic lipid Lipofectamine 2000. Thus, our study con-
firms that tricyclo-DNA oligonucleotides are promising
antisense agents with a potential for therapeutic applica-
tions.
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